Solara Active Pharma Sciences Approves Grant of 4,70,000 ESOPs
Solara Active Pharma Sciences Ltd 路 Others (Uncategorized) 路 16 Oct 2026, 7:28 pm
Solara Active Pharma Sciences Approves Grant of 4,70,000 ESOPs Solara Active Pharma Sciences Limited's Nomination and Remuneration Committee approved the grant of 4,70,000 stock options to eligible employees under the Solara Employee Stock Option Plan 2024 on 16th Oct'26. The options cover 4,70,000 equity shares at an exercise price of Rs. 375 per share. Grantees must exercise the options within 120 days from the vesting date, after which unexercised options will lapse.
Original exchange filing (PDF)
More announcements from Solara Active Pharma Sciences Ltd
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026 路 23 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders .... 路 18 Oct 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 路 17 Oct 2026
- Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026 路 17 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA .... 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options. 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter .... 路 16 Oct 2026
